Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings

Daniel O’Brien¹,²,³, Tim Spelman⁴,⁵, Jane Greig¹, James McMahon⁶, Charles Ssonko¹, Esther Casas⁷, Anita Mesic⁸, Philipp Du Cros¹ and Nathan Ford⁶

¹Corresponding author: Daniel O’Brien, Manson Unit, Médecins Sans Frontières, Lower Ground Floor, Chancery Exchange, 10 Furnival St, London EC4A 1AB, United Kingdom. (Daniel.obrien@amsterdam.msf.org)

Abstract

Introduction: An increasing proportion of adult patients initiating antiretroviral therapy (ART) in resource-limited settings are aged >50 years. Older populations on ART appear to have heightened risk of death, but little is known about factors influencing mortality in this population.

Methods: We performed a retrospective observational multisite cohort study including all adult patients (≥15 years) initiating ART between 2003 and 2013 in programmes supported by Médecins Sans Frontières across 12 countries in Africa, Asia and Europe. Patients were stratified into two age groups, >50 years and 15 to 50 years. A Cox proportional hazards model was used to explore factors associated with mortality.

Results: The study included 41,088 patients: 2591 (6.3%) were aged >50 years and 38,497 (93.7%) were aged 15 to 50 years. The mortality rate was significantly higher in the age group >50 years [367 (14.2%) deaths; mortality rate 7.67 deaths per 100 person-years (95% confidence interval, CI: 6.93 to 8.50)] compared to the age group 15 to 50 years [3788 (9.8%) deaths; mortality rate 4.18 deaths per 100 person-years (95% CI: 4.05 to 4.31)], p < 0.0001. Higher CD4 levels at baseline were associated with significantly reduced mortality rates in the 15 to 50 age group but this association was not seen in the >50 age group. WHO Stage 4 conditions were more strongly associated with increased mortality rates in the 15 to 50 age group compared to populations >50 years. WHO Stage 3 conditions were associated with an increased mortality rate in the 15 to 50 age group but not in the >50 age group. Programme region did not affect mortality rates in the >50 age group; however being in an Asian programme was associated with a 36% reduced mortality rate in populations aged 15 to 50 years compared to being in an African programme. There was a higher overall incidence of Stage 3 WHO conditions in people >50 years (12.8/100 person-years) compared to those 15 to 50 years (8.1/100 person-years) (p < 0.01). The rate of Stage 4 WHO conditions was similar (5.8/100 versus 6.1/100 respectively, p = 0.52). Mortality rates on ART associated with the majority of specific WHO conditions were similar between the 15 to 50 and >50 age groups.

Conclusions: Older patients on ART in resource-limited settings have increased mortality rates, but compared to younger populations this appears to be less influenced by baseline CD4 count and WHO clinical stage. HIV treatment programmes in resource-limited settings need to consider risk factors associated with mortality on ART in older populations, which may differ to those related to younger adults.

Keywords: Africa; antiretroviral therapy; Asia; opportunistic infections; older populations; mortality.
Risk factors for mortality of adults on ART in resource-limited settings include severe immunosuppression, advanced WHO stage, low BMI, male sex, anaemia and lack of free access to care [12–14], but it is not known if these risk factors apply equally to patients aged > 50 years at initiation. Opportunistic infections (OIs) are common causes of early mortality in patients initiating ART in resource-limited settings [15–17], and because immune function decreases with age it may be that older populations are at increased risk of OIs such as tuberculosis (TB) [18]. However, there is limited data available regarding the relative incidence and impact on mortality of specific HIV-associated conditions in those aged > 50 years compared to younger populations in resource-limited settings. There is also little known about the impact on mortality of co-morbidities in these populations, which may be greater in older patients.

Our study aims to determine mortality rates and factors associated with mortality on ART for older individuals compared to younger individuals in a large, multicentric database of HIV treatment in Médecins Sans Frontières (MSF) programmes in Africa, Asia and Eastern Europe over 10 years. We compared the incidence of WHO Stage 3 or 4 conditions between older and younger individuals and determined the ART outcomes of older individuals with WHO Stage 3 or 4 conditions diagnosed at baseline compared to younger individuals.

Methods

Study setting and population

This is a retrospective observational multisite cohort study including all adult patients (≥15 years) initiating ART between 28 March 2003 and 11 January 2013 in MSF-supported programmes in 12 countries in Africa (Nigeria, Ethiopia, Democratic Republic of Congo, Zambia, Côte d’Ivoire, Republic of Congo, Uganda, Central African Republic and South Sudan), Asia (India and Myanmar) and Eastern Europe (Moldova). Patients were stratified into two age groups, > 50 years and 15 to 50 years.

HIV-associated clinical conditions, diagnosis and treatment protocols, adherence counselling, patient follow-up, data collection and monitoring, laboratory protocols and drug procurement and supply mechanisms were standardized across MSF programmes [19]. Treatment sites included hospital settings and peripheral health clinics and were located in urban and rural areas as well as stable and unstable contexts. HIV activities were either vertical or integrated into general health programmes. All sites except those in Myanmar programmes, where MAC prophylaxis did not routinely receive prophylaxis for TB or MAC, apart from those in Myanmar programmes, where MAC prophylaxis was generally provided for patients with CD4 < 50 cells/mm³. CD4 counts were usually monitored using automated methods but HIV viral load was not routinely monitored. All treatment was free.

Data collection and analysis

Routine clinical data were collected on standardized forms at each clinic visit by the treating clinician and entered into a standardized electronic database [Follow-Up and Care of HIV Infection and AIDS (FUCHIA), Epicentre, Paris] in each programme. Data were extracted from individual programme databases, de-identified and analyzed using Stata version 12 (StataCorp, College Station, TX, USA). Categorical variables were summarized using frequencies and percentages and compared using the chi-square test. Continuous variables were summarized using medians and interquartile ranges (IQR). Cox proportional hazards regression was used to compare survival of patients aged > 50 years with those 15 to 50 years of age. Time was measured from the start of ART and was censored at date of death, date of last recorded visit or at the programme end date. Patients who interrupted ART but then recommenced ART at a later date were not excluded. We further used a Cox proportional hazards model to identify factors associated with mortality during the follow up period in those aged > 50 years and in those 15 to 50 years of age at ART initiation. Covariates included, sex, pre-ART CD4 cell count, WHO clinical stage at baseline, BMI and geographical region. Hazard proportionality was assessed through analysis of scaled Schoenfeld residuals. Interactions between model predictors were also tested.
Incidence rates were designated *a priori* to be reported as crude, unadjusted rates. They were calculated on the same cohort as was used for mortality rates and all patients were included regardless of whether they had a WHO Stage 3 or 4 condition already diagnosed at ART baseline. Overall incidence rates for any WHO Stage 3 or 4 condition diagnosed after ART initiation were calculated by dividing the number of occurrences of a Stage 3 or 4 condition after ART initiation by the number of person-years at risk. Patients were censored at death, loss to follow-up or at the time where they had developed a WHO Stage 3 or 4 condition after ART initiation. Patients missing an appointment by more than two months were considered lost to follow-up and censored on the day of their last visit. Disease-specific incidence rates were calculated by dividing the number of first diagnoses of each WHO Stage 3 or 4 condition after ART initiation by the number of person-years at risk. These analyses considered only the WHO Stage 3 or 4 condition of interest and data were censored at death, loss to follow-up or at the time they developed a WHO Stage 3 or 4 condition after ART initiation. If patients were diagnosed with multiple WHO Stage 3 or 4 conditions they were all included; however, each condition was only included once. We used a modified intention-to-treat analysis ignoring treatment included; however, each condition was only included once. We used a modified intention-to-treat analysis ignoring treatment included; however, each condition was only included once. We used a modified intention-to-treat analysis ignoring treatment included; however, each condition was only included once. We used a modified intention-to-treat analysis ignoring treatment included; however, each condition was only included once. We used a modified intention-to-treat analysis ignoring treatment included; however, each condition was only included once.

**Results**

**Cohort characteristics**

The study included 41,088 patients: 2591 (6.3%) aged >50 years and 38,497 (93.7%) aged 15 to 50 years (Table 1). Males accounted for 51.6% (21,184) of the population. Overall 32,606 (79.4%) were in WHO clinical Stages 3 or 4, median CD4 at ART initiation was 121 cells/\(\mu\)L (IQR 48 to 219 cells/\(\mu\)L) and 15,258 (37.1%) had a BMI <18.5. The majority of patients were from Asian programmes (31,698; 77.1%), 9156 (22.3%) were from African programmes and 234 (0.6%) were from European programmes. The median time on ART was 1.7 years (IQR 0.6 to 3.4 years).

There was no difference in the gender ratio or baseline CD4 categories between age groups. However, there was a higher proportion of patients in WHO clinical Stage 4, a lower proportion in WHO clinical Stage 3 \((p<0.01)\) and a higher proportion malnourished \((BMI <18.5; p<0.01)\) in the age group 15 to 50 years compared to >50 years. A higher proportion of patients were from Asian programmes and the median time on ART was slightly longer in the age group 15 to 50 years compared to >50 years \((p<0.01)\) (Table 1).

**Table 1. Baseline characteristics of cohort at ART initiation stratified by age group**

| Baseline characteristic | Overall cohort \((n=41,088)\) | >50 years \((n=2591)\) | 15 to 50 years \((n=38,497)\) | \(p\)-value \((>50\ vs\ 15\ to\ 50\ years)\) |
|-------------------------|-------------------------------|----------------------|-----------------------------|---------------------------------|
| **Age (years)**         | Median (IQR)                  | 34 (29.40)           | 53 (51.57)                  | 33 (29.38)                      | N/A                              |
| Female                  | 19,891 (48.4)                 | 1225 (47.3)          | 18,666 (48.5)               | 0.24*                           |
| Male                    | 21,184 (51.6)                 | 1365 (52.7)          | 19,819 (51.5)               |                                 |
| Not available           | 13 (0.0)                      | 1 (0.0)              | 12 (0.0)                    |                                 |
| **WHO Stage n (%)**     |                               |                      |                             |                                 |
| 1                       | 3722 (9.1)                    | 180 (7.0)            | 3542 (9.2)                  | <0.01*                          |
| 2                       | 3951 (9.6)                    | 277 (10.7)           | 3674 (9.5)                  |                                 |
| 3                       | 20,549 (50.0)                 | 1435 (55.6)          | 19,114 (49.7)               |                                 |
| 4                       | 12,057 (29.3)                 | 635 (24.6)           | 11,422 (29.7)               |                                 |
| Not available           | 809 (2.0)                     | 64 (2.5)             | 745 (1.9)                   |                                 |
| **Baseline CD4 n (%)**  |                               |                      |                             |                                 |
| <200                    | 16,038 (39.0)                 | 882 (34.0)           | 15,156 (39.4)               | 0.65*                           |
| 200 to 499              | 5832 (14.2)                   | 313 (12.1)           | 5519 (14.3)                 |                                 |
| 500+                    | 679 (1.7)                     | 32 (1.2)             | 647 (1.7)                   |                                 |
| Not available           | 18,539 (45.1)                 | 1364 (52.6)          | 17,175 (44.6)               |                                 |
| **BMI n (%)**           |                               |                      |                             |                                 |
| <18.5                   | 15,258 (37.1)                 | 882 (34.0)           | 14,376 (37.3)               | <0.01*                          |
| 18.5 to 25              | 14,201 (34.6)                 | 897 (34.6)           | 13,304 (34.6)               |                                 |
| >25                     | 1399 (3.4)                    | 123 (4.8)            | 1276 (3.3)                  |                                 |
| Not available           | 10,230 (24.9)                 | 689 (26.6)           | 9541 (24.8)                 |                                 |
| **Region n (%)**        |                               |                      |                             |                                 |
| Africa                  | 9156 (22.3)                   | 801 (30.9)           | 8355 (21.7)                 | <0.01                           |
| Asia                    | 31,698 (77.1)                 | 1781 (68.7)          | 29,917 (77.7)               |                                 |
| Europe                  | 234 (0.6)                     | 9 (0.4)              | 225 (1.0)                   |                                 |
| **Duration of ART (years)** | Median (IQR)             | 1.7 (0.6, 3.4)       | 1.4 (0.6, 2.9)              | 1.7 (0.6, 3.5)                  | <0.01                           |

N/A, not applicable; *excludes patients with data “not available”; ART, antiretroviral therapy; IQR, interquartile ratio; BMI, body mass index.
Outcomes
At the time of analysis, 4155 (10.1%) patients had died, 3529 (8.6%) were lost to follow-up, 2489 (6.1%) had transferred out and 30,915 (75.2%) remained on treatment. In the >50 age group, 367 (14.2%) patients had died, 142 (5.5%) were lost to follow-up, 103 (4.0%) had transferred out and 3387 (8.8%) were lost to follow-up, 2386 (6.2%) had transferred out and 28,936 (75.2%) remained on treatment.

Mortality rates
There were 3788 (9.8%) deaths in the 15 to 50 age group over a total follow-up time of 90,656 person-years, corresponding to an incidence rate of 4.18 deaths per 100 person-years of follow-up (95% confidence interval, CI: 4.05, 4.31). This compared to 367 (14.2%) deaths in the >50 age group over a total follow-up time of 4782 person-years with an incidence rate of deaths higher than in the age group 15 to 50 years [7.67 deaths per 100 person-years of follow-up (95% CI: 6.93, 8.50), p < 0.001] (Figure 1).

Predictors of mortality
For populations aged 15 to 50 years, CD4 levels ≥ 200 cells/mm³ at baseline were associated with significantly reduced mortality rates compared to CD4 levels < 200 cells/mm³ (aHR 0.58, 95% CI: 0.52 to 0.66, p < 0.001, for CD4 200 to 499 cells/mm³ and aHR 0.29, 95% CI: 0.18 to 0.47, p < 0.001, for CD4 ≥ 500 cells/mm³ compared with CD4 < 200 cells/mm³). No significant differences in mortality rates were associated with baseline CD4 levels in the >50 age group, although there was a trend towards significantly reduced rates with a baseline of 200 to 499 compared with < 200 cells/mm³ (aHR 0.72, 95% CI: 0.50 to 1.03, p = 0.07, for CD4 < 200 cells/mm³ compared to CD4 200 to 499 cells/mm³) (Table 2). The effect of gender was the same in both age groups, with females having lower mortality rates (aHR 0.73, 95% CI: 0.59 to 0.90 for age > 50 and aHR 0.70, 95% CI: 0.66 to 0.75 for age 15 to 50 years). Increasing BMI was associated with reduced mortality rates in both age groups (aHR 0.49, 95% CI: 0.37 to 0.65 for BMI 18.5 to 25 compared to BMI < 18.5 for the >50 age group, and aHR 0.55, 95% CI: 0.50 to 0.60 for BMI 18.5 to 25 compared to BMI < 18.5 for the 15 to 50 age group).

The influence of baseline clinical WHO stage was more pronounced in the younger age group. Stage 4 conditions were associated with a fourfold increased mortality rate (aHR 3.99, 95% CI: 3.26 to 4.88, p < 0.01, for WHO Stage 4 compared to WHO Stage 1) compared to a twofold increased mortality rate in populations aged > 50 years (aHR 1.93, 95% CI: 1.10 to 3.39, p < 0.02, for WHO Stage 4 compared to WHO Stage 1). Stage 3 conditions were associated with a twofold increase in mortality rate in those aged 15 to 50 years (aHR 2.21, 95% CI: 1.81 to 2.71, p < 0.01, for WHO Stage 3 compared to Stage 1) but were not significantly associated with mortality in the older age group. Finally, programme region was not associated with mortality rates in the age group >50 years, but being in an Asian programme was associated with a reduced mortality in the populations aged 15 to 50 years compared to being in an African programme (0.64, 95% CI: 0.59 to 0.69, p < 0.01).

Incidence of WHO Stage 3 and 4 conditions
There was a higher overall incidence of Stage 3 WHO conditions in people aged >50 years (12.80/100 person-years) compared to those aged 15 to 50 years (8.10/100 person-years) (p < 0.001); however, the overall rate of Stage 4 WHO conditions was similar (5.83/100 versus 6.05/100 respectively, p = 0.52) (Table 3). The overall incidence rates for both Stage 3 and Stage 4 WHO conditions were higher in those who were male, had a BMI < 18.5 kg/m², had a baseline CD4 count < 200 cells/mm³ and were in African programmes (Table 4).

For disease-specific incidence rates, the following Stage 3 conditions were more common in the >50 year age group: weight loss > 10%, unexplained diarrhoea, unexplained fever, oral candidiasis, pulmonary TB, bacterial pneumonia and severe bacterial infections. The only Stage 4 condition more common in the >50 age group was wasting syndrome (Table 3).

Mortality associated with WHO Stage 3 and 4 conditions
Associations between mortality (i.e. after 36 months of ART) and initial presentation of WHO Stage 3 and 4 conditions (i.e. during the first six months of ART) are shown in Table 5. In the >50 age group Kaposi’s sarcoma, candidiasis of the oesophagus/trachea/bronchi/lungs and toxoplasmosis were associated with the highest mortality rates. The following conditions were associated with an increased mortality rate in the >50 age group compared with the 15 to 50 age group: oral candidiasis (HR 1.75, 95% CI: 0.97 to 3.17, p = 0.06), oral hairy leukoplaikia (HR 3.94, 95% CI: 1.75 to 8.85, p = 0.01) and Kaposi’s sarcoma (HR 2.40, 95% CI: 1.05 to 5.51, p = 0.04).

Discussion
This study is consistent with previous findings that mortality rates on ART in resource-limited settings are higher in older populations, with a mortality rate nearly two times greater in populations aged >50 years compared with those aged 15 to 50 years. In a study across four sub-Saharan African countries the death rate one year after ART initiation was highest among the age group ≥ 50 years (6.0%) compared with adults...
Table 2. Cox proportional hazards model showing unadjusted and adjusted associations between baseline characteristics and mortality rates on ART

| Variable        | uHR age > 50 years (95% CI) | p    | aHR age > 50 years (95% CI) | p    | uHR age 15 to 50 years (95% CI) | p    | aHR age 15 to 50 years (95% CI) | p    |
|-----------------|-----------------------------|------|----------------------------|------|--------------------------------|------|--------------------------------|------|
| Gender          |                             |      |                            |      |                                |      |                                |      |
| Male            | 1                           |      | 1                          |      | 1                               |      | 1                               |      |
| Female          | 0.71 (0.58, 0.88)           | <0.01| 0.73 (0.59, 0.90)          | <0.01| 0.64 (0.60, 0.69)              | <0.01| 0.70 (0.66, 0.75)              | <0.01|
| CD4 count       |                             |      |                            |      |                                |      |                                |      |
| < 200           | 1                           |      | 1                          |      | 1                               |      | 1                               |      |
| 200 to 499      | 0.65 (0.46, 0.94)           | 0.02 | 0.72 (0.50, 1.03)          | 0.07 | 0.46 (0.41, 0.52)              | <0.01| 0.58 (0.52, 0.66)              | <0.01|
| ≥ 500           | 0.51 (0.16, 1.61)           | 0.25 | 0.81 (0.25, 2.56)          | 0.71 | 0.25 (0.15, 0.40)              | <0.01| 0.29 (0.18, 0.47)              | <0.01|
| Missing         | 1.01 (0.81, 1.25)           | 0.96 | 0.91 (0.72, 1.14)          | 0.42 | 1.05 (0.98, 1.12)              | 0.20 | 1.00 (0.93, 1.07)              |      |
| WHO stage       |                             |      |                            |      |                                |      |                                |      |
| 1               |                             |      |                            |      |                                |      |                                |      |
| 2               | 1.16 (0.61, 2.22)           | 0.64 | 1.22 (0.64 to 2.33)        | 0.55 | 1.06 (0.81, 1.38)              | 0.67 | 0.94 (0.72, 1.23)              | 0.67 |
| 3               | 1.68 (0.98, 2.89)           | 0.06 | 1.51 (0.87, 2.62)          | 0.14 | 2.70 (2.21, 3.29)              | <0.01| 2.21 (1.81 to 2.71)            | <0.01|
| 4               | 2.44 (1.40, 4.23)           | <0.01| 1.93 (1.10 to 3.39)        | 0.02 | 5.33 (4.36, 6.50)              | <0.01| 3.99 (3.26, 4.88)              | <0.01|
| BMI             |                             |      |                            |      |                                |      |                                |      |
| < 18.5          | 1                           |      | 1                          |      | 1                               |      | 1                               |      |
| 18.5 to 25      | 0.45 (0.34, 0.59)           | <0.01| 0.49 (0.37, 0.65)          | <0.01| 0.45 (0.41, 0.49)              | <0.01| 0.55 (0.50, 0.60)              | <0.01|
| > 25            | 0.20 (0.08, 0.48)           | <0.01| 0.20 (0.07, 0.54)          | 0.02 | 0.33 (0.25, 0.45)              | <0.01| 0.55 (0.41 to 0.73)            | <0.01|
| Missing         | 1.21 (0.96, 1.52)           | 0.11 | 1.32 (1.04, 1.68)          | 0.03 | 1.31 (1.22, 1.41)              | <0.01| 1.48 (1.37, 1.59)              | <0.01|
| Region          |                             |      |                            |      |                                |      |                                |      |
| Africa          | 1                           |      | 1                          |      | 1                               |      | 1                               |      |
| Asia            | 1.16 (0.91, 1.47)           | 0.22 | 1.1 (0.87, 1.41)           | 0.43 | 0.77 (0.71, 0.83)              | <0.01| 0.64 (0.59, 0.69)              | <0.01|
| Europe          |                            |      |                            |      |                                |      |                                |      |
| uHR, unadjusted hazard ratio; aHR, adjusted hazard ratio; BMI, body mass index; CI, confidence interval; ART, antiretroviral therapy. Values in bold values indicate those that reached statistical significance ($p < 0.05$).
40 to 49 years (5.1%), 25 to 39 years (4.5%) and 15 to 24 years (4.4%; \( p = 0.0001 \) [4]. In a South African cohort, after seven years of ART mortality was two times higher in patients ≥50 years of age [25]. The reasons for this are likely multi-factorial and include the inherent increased mortality with age due to senescence and non-communicable diseases. However, it may also include an increased susceptibility to OIs and less effective responses to ART as suggested by previous studies showing reduced immune recovery in older populations [2,4,5,26].

We found that the influence of baseline CD4 counts on mortality rates appeared to be less pronounced in older populations. Those aged 15 to 50 years having CD4 counts below 200 cells/mm\(^3\) experienced a significantly increased mortality rate compared to those with CD4 counts ≥200 cells/mm\(^3\). However, in populations ≥50 years, although there was a trend to decreased mortality in those with higher CD4 counts; this effect was not large and did not reach significance in our study. This may indicate an increased influence of non-AIDS-defining illnesses (e.g. cardiovascular, renal and liver disease, and cancer) in older populations that may blunt the effect of baseline immune suppression on mortality. Nevertheless, the relationship between immune status and survival remains important: a recent study from South Africa found that the effect of older age on mortality was increased at lower CD4 counts [5].

We also found a less pronounced influence of baseline WHO stage on mortality rates in older populations. Advanced WHO stage is strongly associated with increased mortality on ART in resource-limited settings [16]; however, the magnitude of the influence was two times less for WHO Stage 4 and non-significant for WHO Stage 3 in older populations. Once again this may be due to increased non-AIDS-defining illnesses in older populations.

### Table 3. Incidence of WHO Stage 3 and 4 conditions on ART stratified by age group

| Condition                                         | All patients | Aged >50 years | Aged 15 to 50 years | Comparison of incidence by age group |
|---------------------------------------------------|--------------|----------------|--------------------|--------------------------------------|
|                                                   | Count (%)    | Incidence (per 100 person-years) | Count (%)    | Incidence (per 100 person-years) | Count (%)    | Incidence (per 100 person-years) | p-value (>50 vs 15 to 50) |
| Weight loss >10%                                  | 650 (1.6)    | 1.77           | 53 (2.1)           | 1.11                                  | 597 (1.6)    | 0.66                                  | <0.01                  |
| Diarrhoea, unexplained                            | 510 (1.2)    | 1.51           | 48 (1.9)           | 1.00                                  | 462 (1.2)    | 0.51                                  | <0.01                  |
| Fever, unexplained                                | 356 (0.9)    | 0.90           | 26 (1.0)           | 0.54                                  | 330 (0.9)    | 0.36                                  | 0.05                   |
| Oral candidiasis                                  | 1752 (4.3)   | 5.12           | 161 (6.2)          | 3.37                                  | 1591 (4.1)   | 1.75                                  | <0.01                  |
| Pulmonary TB                                      | 2304 (5.6)   | 6.05           | 177 (6.8)          | 3.70                                  | 2127 (5.5)   | 2.35                                  | <0.01                  |
| Bacterial pneumonia                              | 434 (1.1)    | 1.17           | 35 (1.4)           | 0.73                                  | 399 (1.0)    | 0.44                                  | <0.01                  |
| Bacterial infections, severe, including pneumonia | 368 (0.9)    | 0.98           | 29 (1.1)           | 0.61                                  | 339 (0.9)    | 0.37                                  | <0.01                  |
| Oral hairy leukoplakia                            | 1268 (3.1)   | 2.69           | 65 (1.3)           | 1.36                                  | 1203 (3.1)   | 1.33                                  | 0.85                   |
| Lymph node TB                                     | 58 (0.1)     | 0.10           | 2 (0.1)            | 0.04                                  | 56 (0.2)     | 0.06                                  | 0.68                   |
| Overall Stage 3                                    | 7954 (19.4)  | 20.90          | 612 (23.6)         | 12.80                                 | 7342 (19.1)  | 8.10                                  | <0.01                  |
| Wasting syndrome by HIV/stunting/severe malnutrition | 339 (0.8)    | 0.90           | 27 (1.0)           | 0.56                                  | 312 (0.8)    | 0.34                                  | 0.01                   |
| Cryptococcosis extrapulmonary                      | 322 (0.8)    | 0.65           | 15 (0.6)           | 0.31                                  | 307 (0.8)    | 0.34                                  | 0.77                   |
| Pneumocystis pneumonia                            | 328 (0.8)    | 0.62           | 13 (0.5)           | 0.27                                  | 315 (0.8)    | 0.35                                  | 0.78                   |
| Toxoplasmosis of the brain                        | 421 (1.0)    | 0.88           | 21 (0.8)           | 0.44                                  | 400 (1.0)    | 0.44                                  | 0.98                   |
| Penicillium marneffei infection                   | 90 (0.2)     | 0.16           | 3 (0.1)            | 0.06                                  | 87 (0.2)     | 0.10                                  | 0.47                   |
| Candidiasis oesophagus/trachea/bronchi/lungs      | 453 (1.1)    | 1.08           | 29 (1.1)           | 0.61                                  | 424 (1.1)    | 0.47                                  | 0.18                   |
| Extrapulmonary TB                                 | 1886 (4.6)   | 3.51           | 72 (2.8)           | 1.51                                  | 1814 (3.1)   | 2.00                                  | 0.02                   |
| Lymphoma                                          | 14 (0.0)     | 0.02           | 0 (0.0)            | 0                                     | 14 (0.0)     | 0.02                                  | 0.39                   |
| Herpes simplex infection                          | 238 (0.6)    | 0.50           | 13 (0.5)           | 0.27                                  | 225 (0.6)    | 0.23                                  | 0.75                   |
| Non-TB mycobacteria infection                     | 826 (2.0)    | 1.64           | 37 (1.4)           | 0.77                                  | 791 (2.1)    | 0.87                                  | 0.47                   |
| Mycosis disseminated                              | 289 (0.7)    | 0.63           | 16 (0.6)           | 0.33                                  | 273 (0.7)    | 0.30                                  | 0.68                   |
| Kaposi’s sarcoma                                  | 236 (0.6)    | 0.55           | 15 (0.6)           | 0.31                                  | 221 (0.6)    | 0.24                                  | 0.34                   |
| Cytomegalovirus infection                         | 187 (0.5)    | 0.44           | 12 (0.5)           | 0.25                                  | 175 (0.5)    | 0.19                                  | 0.38                   |
| Overall Stage 4                                    | 5762 (14.0)  | 11.88          | 279 (10.8)         | 5.83                                  | 5483 (14.2)  | 6.05                                  | 0.52                   |

ART, antiretroviral therapy; TB, tuberculosis. Values in bold values indicate those that reached statistical significance (\( p < 0.05 \)).
Factors associated with mortality common to both age groups were male gender and malnutrition. Consistent with many other studies, men have poorer outcomes on ART [5,27] and this finding likely reflects poorer health-seeking behaviour, leading to later disease presentation and diagnosis, as well as reduced health literacy and adherence to treatment. Increased efforts are required to improve the understanding of the reasons responsible in order to address this issue. Likewise prevention and treatment of malnutrition, including micronutrient deficiencies, are important if mortality rates on ART are to be reduced.

We found no influence of geographical region on mortality rates in older age groups, whereas in younger age groups programmes in Asia had a 36% reduction in mortality rate. The reasons for this are not clear but might include the possibility that Asian populations aged <50 have a lower incidence of co-morbidities including OIs and non-HIV-related conditions, but this difference disappears in older cohorts. This is supported by findings from this study where the incidence of WHO conditions was higher in African cohorts and by previous research that showed the rate of OIs on ART was higher in African cohorts than Asian cohorts, with for example pulmonary TB and oral candidiasis being three times more frequent in African cohorts [15].

We have also reported for the first time the incidence rates for specific WHO Stage 3 and 4 conditions in older populations and their effects on mortality during ART compared to younger populations. We found an increased rate of Stage 3 OIs in older populations, including individual conditions such as pulmonary TB and bacterial pneumonia. This finding likely reflects an increased susceptibility to infections due to immune senescence in older compared to younger populations. However, there was no difference in the rate of Stage 4 OIs. This finding may have been influenced by the fact that younger populations had a higher proportion of patients in WHO clinical Stage 4 at baseline. If this reflected a more advanced stage of disease progression, it may have made them more susceptible to developing other Stage 4 illnesses on ART.

There was no increased mortality associated with the majority of specific WHO Stage 3 and 4 conditions in older populations compared with younger populations. One notable exception was Kaposi’s sarcoma, which had a mortality rate more than two times greater in older populations; this higher rate may reflect a general tendency to higher mortality rates associated with cancer in older populations.

This study provides important data for clinicians looking after older individuals with HIV on ART in resource-limited settings: it will help to guide the approach to their management with such things as the relative incidence and impact of WHO-associated conditions and predictors of mortality. Furthermore, it will assist project planners allocate resources for population-based health initiatives as they better understand the specific needs of this increasing population. These needs include the ability to address non-AIDS-defining illnesses and those of senescence such as hypertension, diabetes and renal and cardiovascular diseases. It also suggests that a wider range of services addressing the specific

Table 4. Overall incidence rates of WHO Stage 3 and 4 conditions stratified by age, gender, BMI, baseline CD4 count and region

| Age (years) | WHO Stage 3 condition | p * | WHO Stage 4 condition | p * |
|------------|-----------------------|-----|-----------------------|-----|
| > 50       | 12.80 (10.63, 15.28)  | <0.001 | 5.83 (5.32, 6.38)  | 0.52 |
| 15 to 50   | 8.10 (6.45, 10.07)    |       | 6.05 (5.59, 6.54)  |     |
| Gender     |                       |       |                       |     |
| Male       | 12.96 (12.26, 13.69)  | <0.001 | 7.98 (7.42, 8.58)  | p <0.001 |
| Female     | 7.94 (7.44, 8.55)     |       | 3.92 (3.38, 4.74)  |     |
| BMI (kg/m²) |                      |       |                       |     |
| <18.5      | 10.97 (10.33, 11.64)  | p <0.001 | 6.89 (6.37, 7.44)  | p <0.001 |
| 18.5 to 25 | 6.22 (5.70, 6.78)     |       | 2.97 (2.64, 3.33)  |     |
| >25        | 0.29 (0.17, 0.43)     |       | 0.24 (0.09, 0.42)  |     |
| Missing    | 3.42 (3.02, 3.84)     |       | 1.78 (1.49, 2.10)  |     |
| Baseline CD4 count (cells/mm³) | |       |                       |     |
| <200       | 10.24 (9.62, 10.89)   | p <0.001 | 6.30 (5.77, 6.84)  | p <0.001 |
| 200 to 499 | 2.51 (2.13, 2.95)     |       | 0.95 (0.76, 1.17)  |     |
| ≥500       | 0.21 (0.09, 0.37)     |       | 0.12 (0.05, 0.22)  |     |
| Missing    | 7.94 (7.37, 8.53)     |       | 4.51 (95% CI: 4.06, 5.00) |     |
| Region     |                       |       |                       |     |
| Africa     | 16.09 (15.28, 16.91)  | p <0.001 | 7.80 (7.23, 8.40)  | p <0.001 |
| Asia       | 4.60 (4.24, 4.98)     |       | 3.96 (3.59, 4.35)  |     |
| Europe     | 0.21 (0.06, 0.39)     |       | 0.12 (0.04, 0.26)  |     |

*Bonferroni-adjusted p-value; BMI, body mass index; CI, confidence interval.

O’Brien D et al. Journal of the International AIDS Society 2016, 19:20665
http://www.jiasociety.org/index.php/jias/article/view/20665 | http://dx.doi.org/10.7448/IAS.19.1.20665
| WHO condition (during first six months ARV) | Mortality all patients | Mortality age | Mortality age | Mortality age |
|--------------------------------------------|-----------------------|--------------|--------------|--------------|
| WHO Stage 3 condition                      |                       |              |              |              |
| Weight loss > 10%                          | 2.51 (1.72, 3.64), <0.001 | 2.61 (1.75, 3.87), <0.001 | 1.49 (0.47, 4.67), 0.497 | 1.07 (0.32, 3.56), 0.908 |
| Diarrhoea, unexplained                     | 1.80 (1.15, 2.83), 0.011 | 1.93 (1.20, 3.12), 0.007 | 0.84 (0.21, 3.40), 0.808 | 0.83 (0.19, 3.59), 0.801 |
| Fever, unexplained                         | 2.31 (1.47, 3.64), <0.001 | 2.53 (1.59, 4.03), <0.001 | 0.75 (0.10, 5.35), 0.773 | 0.55 (0.07, 4.11), 0.558 |
| Oral candidiasis                           | 1.61 (1.28, 2.02), <0.001 | 1.57 (1.22, 2.00), <0.001 | 1.47 (0.83, 2.60), 0.186 | 1.75 (0.97, 3.17), 0.064 |
| Pulmonary TB                               | 1.97 (1.60, 2.42), <0.001 | 2.06 (1.66, 2.56), <0.001 | 1.15 (0.54, 2.45), 0.727 | 1.02 (0.47, 2.21), 0.956 |
| Bacterial pneumonia                        | 2.01 (1.32, 3.06), 0.001 | 2.10 (1.35, 3.26), 0.001 | 1.19 (0.29, 4.79), 0.811 | 1.08 (0.25, 4.63), 0.914 |
| Bacterial infections, severe, including pneumonia | 1.92 (1.06, 3.48), 0.031 | 2.03 (1.09, 3.78), 0.026 | 0.99 (0.14, 7.11), 0.996 | 1.10 (0.14, 8.61), 0.930 |
| Oral hairy leukoplaikia                    | 0.99 (0.73, 1.34), 0.951 | 0.91 (0.65, 1.27), 0.579 | 1.98 (0.93, 4.24), 0.077 | 3.94 (1.75, 8.85), 0.001 |
| Lymph node TB                              | 0.53 (0.07, 3.75), 0.523 | 0.57 (0.08, 4.07), 0.577 | ** | ** |
| WHO Stage 4 condition                      |                       |              |              |              |
| Wasting syndrome by HIV/stunting/severe malnutrition | 3.73 (2.49, 5.59), <0.001 | 4.15 (2.72, 6.32), <0.001 | 1.27 (0.31, 5.11), 0.741 | 0.64 (0.15, 2.73), 0.548 |
| Cryptococcosis extrapulmonary              | 3.04 (2.02, 4.60), <0.001 | 3.38 (2.23, 5.10), <0.001 | ** | ** |
| Pneumocystis pneumonia                     | 1.95 (1.13, 3.37), 0.016 | 2.16 (1.25, 3.73), 0.006 | ** | ** |
| Toxoplasmosis of the brain                 | 2.95 (1.99, 4.39), <0.001 | 3.03 (2.03, 4.54), <0.001 | 3.67 (0.51, 26.23), 0.195 | 2.02 (0.27, 14.94), 0.492 |
| Penicillium marneffei infection            | 2.73 (1.47, 5.09), 0.002 | 3.03 (1.63, 5.65), <0.001 | ** | ** |
| Candidiasis oesophagus/trachea/bronchi/lungs | 2.96 (2.07, 4.23), <0.001 | 2.89 (1.97, 4.23), <0.001 | 3.41 (1.26, 9.22), 0.016 | 2.15 (0.75, 6.15), 0.153 |
| Extrapulmonary TB                          | 2.43 (1.87, 3.16), <0.001 | 2.60 (1.99, 3.40), <0.001 | 0.91 (0.22, 3.66), 0.891 | 0.71 (0.17, 2.90), 0.631 |
| Lymphoma                                   | 5.81 (1.45, 23.27), 0.013 | 6.11 (1.53, 24.45), 0.011 | ** | ** |
| Herpes simplex infection                   | 1.10 (0.52, 2.31), 0.807 | 1.06 (0.47, 2.36), 0.889 | 1.30 (0.18, 9.27), 0.796 | 2.41 (0.29, 20.05), 0.417 |
| Non-TB mycobacteria infection             | 2.68 (2.02, 3.56), <0.001 | 2.87 (2.15, 3.84), <0.001 | 1.04 (0.26, 4.22), 0.953 | 0.66 (0.16, 2.73), 0.571 |
| Mycosis disseminated                      | 1.62 (0.87, 3.02), 0.128 | 1.48 (0.74, 2.97), 0.266 | 2.17 (0.54, 8.77), 0.276 | 2.75 (0.58, 12.97), 0.201 |
| Kaposi’s sarcoma                           | 6.34 (4.54, 8.87), <0.001 | 5.84 (4.01, 8.49), <0.001 | 8.04 (3.75, 17.24), <0.001 | 2.40 (1.05, 5.51), 0.038 |
| Cytomegalovirus infection                  | 2.49 (1.47, 4.21), 0.001 | 2.78 (1.64, 4.71), <0.001 | ** | ** |

**No diagnosis of this WHO condition made in this age group. uHR, unadjusted hazard ratio; CI, confidence interval; TB, tuberculosis.
health and social needs of older populations need to be integrated into HIV programmes to provide older populations in their cohorts with more effective care that may reduce their increased mortality relative to younger populations. Finally, as there is little known about what it is like living with HIV for older patients in resource-limited settings, our findings may help to stimulate further social science research to explore this issue.

Important limitations of our study included the lack of information on non-AIDS-defining illnesses and particularly chronic co-morbidities, as well as general mortality rates in non-HIV-infected elderly populations in the regions where the study was undertaken. Therefore we were unable to determine whether HIV conferred an additional increased mortality in older populations in these regions above the inherent increased mortality associated with age due to senescence and other co-morbidities. In addition, as with any observational study, there may have been unmeasured confounders that may have affected the outcomes. Furthermore, as a proportion of the cohort were lost to follow-up and some of these may have died or developed HIV-associated conditions, we may have underestimated the mortality and incidence of specific conditions during ART. Additionally, the cohort size in the group aged >50 years compared with that 15 to 50 years was small, limiting the confidence around the strength of the associations in that age group. Baseline differences of WHO stage and BMI between the age groups may also have influenced the unadjusted incidence rates of WHO conditions. Furthermore, due to the reliance on basic investigations to support clinical assessment in the diagnosis of HIV-associated conditions, there may have been some inaccuracies in the diagnosis. There was also a relatively high rate of missing CD4 values at the start of ART, due to testing being unavailable in some sites or not used if WHO stage confirmed ART eligibility, and this may have influenced the observed associations with CD4. Finally, as a high proportion of the cohort was from Asia, the findings may be less applicable in African settings.

In conclusion, older patients on ART in resource-limited settings had increased mortality rates, but compared to younger populations this was less influenced by differences in baseline CD4 count and WHO clinical stage. The rate of WHO Stage 3 clinical conditions diagnosed during ART was higher in older cohorts but mortality rates associated with the majority of these specific conditions were similar between age groups. HIV treatment programmes in resource-limited settings need to be adapted to consider risk factors associated with mortality on ART in older populations, which, as suggested from the findings of this study, may differ to those for younger adults.

Authors’ affiliations
1Manson Unit, Médecins Sans Frontières, London, United Kingdom; 2Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia; 3Department of Infectious Diseases, Geelong Hospital, Geelong, Australia; 4Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; 5Centre for Population Health, Burnet Institute, Melbourne, Australia; 6Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia; 7Public Health Department, Médecins Sans Frontières, Amsterdam, The Netherlands; 8Centre for Infectious Diseases Epidemiology Research, University of Cape Town, Cape Town, South Africa

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DOB and NF conceived the study, TS and JG collected and analyzed the data. All authors contributed to the interpretation of the findings. DOB wrote the first draft of the paper. All authors contributed to the subsequent drafts and approved the final version.

References
1. Negin J, Cumming RG. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ. 2010; 88:847–53.
2. Greig J, Casax EC, O’Brien DP, Mills EI, Ford N. Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries. AIDS (London, England). 2012;26(Suppl 1): S31–7.
3. Hontelez JA, de Vlas Sj, Baltussen R, Newell ML, Bakker R, Tanser F, et al. The impact of antiretroviral treatment on the age distribution of the HIV epidemic in sub-Saharan Africa. AIDS (London, England). 2012;26(Suppl 1): S29–30.
4. Eduardo E, Lamb MR, Kandula N, Howard A, Mugisha V, Kimanga D, et al. Characteristics and outcomes among older HIV-positive adults enrolled in HIV programs in four sub-Saharan African countries. PLoS One. 2014;9:e103864.
5. Cornell M, Johnson L, Schomaker M, Tanser F, Maskew M, Wood R, et al. Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. Lancet HIV. 2015;2:368–e75.
6. Nogueiras M, Navarro G, Antion E, Sala M, Cervantes M, Amengual M, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis. 2006; 6:159.
7. Reuter S, Dette M, Kaiser R, Lengauer T, Fatkenheuer G, Rockstroh JK, et al. Risk factors associated with older age in treatment-naive HIV-positive patients. Interseeul. 2012;55:147–53.
8. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabín CA, Smith CJ, d’Minnio Monforte A, Battagty M, Gabiano C, et al. Response to combination antiretroviral therapy: variation by age. AIDS (London, England). 2008;22:1463–73.
9. Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, et al. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther. 2010; 7:45.
10. Maslensk A, Brennan AT, MacPhail AP, Sanne IM, Fox MP. Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Phys AIDS Care. 2012;11:57–65.
11. Mills EI, Ramohano A, Awoseso N. Ageing faster with AIDS in Africa. Lancet. 2011;377:1311–3.
12. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Cefta S, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retrovir. 2008;24:555–60.
13. May M, Boule A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376: 449–57.
14. Johannesen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.
15. Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, et al. Incidence of WHO stage 3 and 4 conditions following initiation of antiretroviral therapy in resource limited settings. PLoS One. 2012;7:e52019.
16. Marshall CS, Curtis AJ, Spelman T, O’Brien DP, Greig J, Shanks L, et al. Impact of HIV-associated conditions on mortality in people commencing antiretroviral therapy in resource limited settings. PLoS One. 2013;8:e68445.
17. Etard JF, Ndaiye I, Thierrier-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181–9.
18. Schaaf HS, Collins A, Behker A, Davies PD. Tuberculosis at extremes of age. Respirology. 2010;15:747–63.
19. Lyen L. Clinical HIV/AIDS care guidelines for resource-poor settings. 2nd ed. Brussels: Médecins Sans Frontières Operational Centre; 2006.
20. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: WHO; 2010.
21. World Health Organization. TB/HIV: a clinical manual. Geneva, Switzerland: WHO; 2004.
22. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. In: Recommendations for a public health approach. Geneva: WHO; 2010.
23. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Geneva: WHO; 2006.
24. Médecins Sans Frontières Ethics Review Board standard operating procedures [Internet]. [cited 2016 Jan 5]; Available from: http://fieldresearch.msf.org/msf/handle/10144/294968
25. Boule A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563–72.
26. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029–38.
27. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27:417–25.
Author/s:
O'Brien, D; Spelman, T; Greig, J; McMahon, J; Ssonko, C; Casas, E; Mesic, A; Du Cros, P; Ford, N

Title:
Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings

Date:
2016-01-14

Citation:
O'Brien, D., Spelman, T., Greig, J., McMahon, J., Ssonko, C., Casas, E., Mesic, A., Du Cros, P. & Ford, N. (2016). Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 19 (1), https://doi.org/10.7448/IAS.19.1.20665.

Persistent Link:
http://hdl.handle.net/11343/258089

File Description:
Published version

License:
CC BY